Alternative Splicing and CaV ‐Associated Channelopathies
WIREs RNA · 2025
DOI: 10.1002/wrna.70016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs RNA, 2025. Verfasst von Willy Munyao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of RNA Biology and Molecular Neuroscience, Department of Biological Sciences, St. John's University, Queens, New York, USA. Hauptthemen laut MEDLINE: Alternative Splicing, Channelopathies, Calcium Channels. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 360 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Voltage‐gated calcium channels (VGCCs) are multi‐subunit ion channel proteins that control and regulate a wide array of physiological processes. Their dysfunction has been implicated in several neurological, cardiac, psychiatric, endocrine, oncogenic, and muscular disorders. The diverse and specialized cellular functions involving VGCC‐mediated calcium signaling stem from two primary mechanisms: differential and cell‐specific expression of pore‐forming (α1) and auxiliary subunit genes, and extensive alternative splicing of their pre‐mRNA. All the 10 α1‐encoding genes undergo alternative splicing to generate a wide array of cell‐specific CaV variants with distinct biophysical, pharmacological, and protein–protein interaction properties. This proteomic diversity and the associated cell‐specific expression signature of CaV splice variants are tightly regulated by trans ‐acting splicing factors—RNA‐binding proteins that control the inclusion or skipping of alternatively spliced exons during post‐transcriptional pre‐mRNA processing. The discovery that several channelopathies are caused by aberrant splicing due to genetic mutations in either cis ‐acting binding elements on the pre‐mRNA or in core splicing machinery components highlights the crucial role of alternative splicing in VGCC‐related pathologies. These insights have opened new therapeutic avenues, as targeting the alternative splicing of disease‐associated specific exons has recently emerged as a novel, promising treatment for neurodevelopmental disorders and channelopathies associated with splicing dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of RNA Biology and Molecular Neuroscience, Department of Biological Sciences, St. John's University, Queens, New York, USA.
- Laboratory of Molecular Physiology and Biophysics, Department of Biological Sciences, St. John's University, Queens, New York, USA.
ORCID-Profile: Willy Munyao, Md Mostafizur Rahman, Samuel A Sabzanov, Elizabeth H Chu, Ruizhi Wang, Zhifei Wang, Yong Yu, Matteo Ruggiu
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Munyao, W., Rahman, M. M., Sabzanov, S. A., Chu, E. H., Wang, R., Wang, Z., Yu, Y., & Ruggiu, M. (2025). Alternative Splicing and CaV ‐Associated Channelopathies. WIREs RNA. https://doi.org/10.1002/wrna.70016
Vancouver
Munyao W, Rahman MM, Sabzanov SA, Chu EH, Wang R, Wang Z, et al. Alternative Splicing and CaV ‐Associated Channelopathies. WIREs RNA. 2025. doi:10.1002/wrna.70016
BibTeX
@article{Munyao2025,
author = {Munyao, Willy and Rahman, Md Mostafizur and Sabzanov, Samuel A and Chu, Elizabeth H and Wang, Ruizhi and Wang, Zhifei and Yu, Yong and Ruggiu, Matteo},
title = {Alternative Splicing and CaV ‐Associated Channelopathies},
journal = {WIREs RNA},
year = {2025},
doi = {10.1002/wrna.70016}
}
EUVIMED